Suppr超能文献

1例肺静脉闭塞病合并肺栓塞患者的病例报告:是否抗凝?

A case report of PVOD patient combined with pulmonary embolism: Anticoagulation or not?

作者信息

Yuan Xiaoling, Hou Xianghe, Guo Weihong, Jiang Haiming, Zheng Junmeng, Paudyal Stuti, Lyu Yanhua

机构信息

Respiratory Department Pathology Department Cardiothoracic Surgery, People's Hospital of Zhongshan City, Zhongshan City Medical Intern, Sun Yat-Sen University, China.

出版信息

Medicine (Baltimore). 2017 Mar;96(13):e6507. doi: 10.1097/MD.0000000000006507.

Abstract

RATIONALE

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH). Oral anticoagulation is confined to patients with idiopathic PAH (IPAH), but no oral anticoagulation has been recommended for PVOD, because occult pulmonary hemorrhage was a common finding in PVOD.

PATIENT CONCERNS

We report a case of PVOD, who was misdiagnosed as IPAH for 5 years with worsening dyspnea and two episodes of pulmonary embolism (PE).

DIAGNOSES

He was confirmed as PVOD combined with PE by biopsy of the explanted lung specimen.

INTERVENTIONS

He took oral anticoagulation, warfarin, to treat his first-time PE in July 2010, and his disease was kept stable for about 4 years, until he discontinued the anticoagulation therapy by himself sometime in 2014. Later on, a life-threatening PE recurred in January 2015, so he resumed the anticoagulation therapy.

OUTCOMES

Fortunately, the bilateral sequential lung transplantation that was performed in July 2015 in time saved his life. He has been living well without dyspnea and the echocardiography showed the normalizations of the once increased pulmonary arterial pressure and the once enlarged right ventricle of his heart. In addition, to the best of my knowledge, he was the first PVOD patient receiving lung transplantation in China.

LESSONS

We recommend that PVOD patients combined with PE should be treated with anticoagulation therapy indefinitely to prevent the recurrence of life-threatening PE until they get a chance for lung transplantation.

摘要

理论依据

肺静脉闭塞性疾病(PVOD)是一种罕见的肺动脉高压(PAH)形式。口服抗凝治疗仅限于特发性PAH(IPAH)患者,但PVOD患者未被推荐使用口服抗凝治疗,因为隐匿性肺出血在PVOD中是常见表现。

患者情况

我们报告一例PVOD患者,该患者被误诊为IPAH达5年,伴有进行性加重的呼吸困难和两次肺栓塞(PE)发作。

诊断

通过对切除的肺标本进行活检,确诊为PVOD合并PE。

干预措施

他于2010年7月开始口服抗凝药物华法林治疗首次发作的PE,病情保持稳定约4年,直到2014年某个时候他自行停用抗凝治疗。后来,2015年1月再次发生危及生命的PE,于是他重新开始抗凝治疗。

结果

幸运的是,2015年7月及时进行的双侧序贯肺移植挽救了他的生命。他现在生活良好,没有呼吸困难,超声心动图显示曾经升高的肺动脉压和曾经扩大的右心室已恢复正常。此外,据我所知,他是中国首例接受肺移植的PVOD患者。

经验教训

我们建议,PVOD合并PE的患者应无限期接受抗凝治疗,以预防危及生命的PE复发,直到他们有机会接受肺移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f0/5380288/73c6743df64c/medi-96-e6507-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验